The Increasing Use Of Targeted Therapies Is Fueling The Market Growth Due To Enhanced Treatment Precision And Reduce Side Effects: Key Factor Driving The Growth In The Cytokine Release Syndrome Management Market

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics._x000D_
_x000D_
What Is the Expected Cytokine Release Syndrome Management Market Size During the Forecast Period?_x000D_
In the recent past, the market size for managing cytokine release syndrome has robustly expanded. It is projected to increase from a valuation of $22.32 billion in 2024 to about $23.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth throughout the historical period is a result of factors like growing healthcare spending, increased public awareness, lifestyle alterations, higher disposable income, the uptake of personalized medical treatments, and the broader utilization of targeted therapies._x000D_
_x000D_
The market for managing cytokine release syndrome is projected to experience significant expansion in the upcoming years. It is anticipated to reach a value of $30.69 billion in 2029, with a compound annual growth rate (CAGR) of 6.5%. This growth within the forecast period can be ascribed to factors such as increased demand for diagnostic apparatus and treatments, escalating government support, heightened demand for potent therapies, a growing elderly population, and ongoing endeavours by both public and private entities. Noteworthy trends during the prediction period encompass devices for non-invasive breast biopsies, strategic cooperations and collaborations, infusion services for antibiotics at home, the rise of innovative drug delivery systems, and the assimilation of electronic health records in infection surveillance._x000D_
_x000D_
Purchase the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp_x000D_
_x000D_
What Are the High-Growth Segments in the Cytokine Release Syndrome Management Market?_x000D_
The cytokine release syndrome management market covered in this report is segmented -_x000D_
_x000D_
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types_x000D_
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications_x000D_
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration_x000D_
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab, Other Monoclonal Antibodies_x000D_
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone, Other Corticosteroids_x000D_
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin, Other Types of Intravenous Immunoglobulin_x000D_
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton's Tyrosine Kinase (BTK) Inhibitors, Other Targeted Agents_x000D_
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents_x000D_
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support_x000D_
_x000D_
Get your free sample here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp_x000D_
_x000D_
What Key Drivers Are Expected to Influence Future Cytokine Release Syndrome Management Market Growth?_x000D_
The cytokine release syndrome management market is forecasted to grow, fuelled by the rising application of targeted therapies. These therapies, whether medicinal or treatment-based, have been designed to directly combat cancer growth and proliferation by impeding molecular targets that facilitate tumor progression. The advantage of these therapies is that they specifically target cancer cells, mitigating damage to healthy cells, advancing treatment efficacy, and reducing the adverse effects that traditional therapies typically exhibit. Cytokine release syndrome management plays an indispensable role in enhancing targeted therapies by regulating drastic inflammatory responses, thus amplifying the safety and efficiency of treatments like CAR-T cell therapy and immune checkpoint inhibitors. For instance, in January 2024, the American Society of Gene and Cell Therapy, a prominent US-based gene and cell therapy institution, announced a 10% surge in gene therapies in Phase III clinical trials in the last quarter of 2023. This was the first increase of this kind since the third quarter of 2022. Consequently, the escalating application of targeted therapies is spearheading the growth of the cytokine release syndrome management market._x000D_
_x000D_
Which Companies Hold the Largest Share Across Different Cytokine Release Syndrome Management Market Segments?_x000D_
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc._x000D_
_x000D_
What Are the Major Trends Shaping the Cytokine Release Syndrome Management Market?_x000D_
Leading businesses in the cytokine release syndrome management market are prioritizing the execution of clinical experiments to create groundbreaking therapies such as host-administered small molecule drugs. These are designed to adjust the immune response and lessen the intensity of cytokine storms, without undermining the body's ability to combat infections or cancer. A host-directed small molecule medication is a low molecular mass compound that focuses on the host's immune signaling routes to control excessive cytokine output, thereby aiding in the regulation of cytokine release syndrome (CRS) by preventing the hyperactivity of the immune system. For example, in April 2025, CytoAgents Inc., a biotech company based in the USA, publicized the successful finalization of the initial dose-scaling group in its Phase 1b/2a clinical trial of CTO1681. This is a host-directed small molecule drug developed for the prevention and treatment of CRS in patients subjected to CAR T-cell therapy. This research medication showed a promising safety profile, with no dose-associated toxic effects or interruptions to CAR T-cell effectiveness. The trial, employing a rolling six dose augmentation design, is being performed to evaluate the security, endurance, and initial efficiency of CTO1681, and to determine the recommended dosage for phase 2._x000D_
_x000D_
Get the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-management-global-market-report_x000D_
_x000D_
What Are the Emerging Geographies for The Cytokine Release Syndrome Management Market Growth?_x000D_
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
Frequently Asked Questions:_x000D_
1. What Is the Market Size and Growth Rate of the Cytokine Release Syndrome Management Market?_x000D_
2. What is the CAGR expected in the Cytokine Release Syndrome Management Market?_x000D_
3. What Are the Key Innovations Transforming the Cytokine Release Syndrome Management Industry?_x000D_
4. Which Region Is Leading the Cytokine Release Syndrome Management Market?_x000D_
_x000D_
Why This Report Matters:_x000D_
_x000D_
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors._x000D_
_x000D_
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends._x000D_
_x000D_
Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.